David Mott - Mersana Therapeutics Chairman of the Board
| MRSN Stock | USD 3.16 0.22 7.48% |
Chairman
Mr. David M. Mott is an Independent Chairman of the Board of the Company. Mr. Mott is the Chairman of the Board at Mersana Therapeutics Inc. He is a General Partner at New Enterprise Associates, where he leads the healthcare investing practice. Before joining NEA, he spent 16 years at MedImmune in roles of increasing responsibility, including Chief Operating Officer, Chief Financial Officer and CEO, building the company from a venturebacked startup into one of the top five biotechnology companies in the world, He led the sale of MedImmune to AstraZeneca in 2007 for 15.6 billion, and at the time of his departure in 2008, MedImmune had annual revenues in excess of 1.5 billion, annual RD in excess of 650 million and approximately 3, 000 employees since 2017.
| Age | 52 |
| Tenure | 7 years |
| Address | 840 Memorial Drive, Cambridge, MA, United States, 02139 |
| Phone | 617 498 0020 |
| Web | https://www.mersana.com |
Mersana Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3813) % which means that it has lost $0.3813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6624) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of April 2024, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to drop to -1.11. At this time, Mersana Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 30th of April 2024, Asset Turnover is likely to grow to 0.23, while Total Assets are likely to drop about 180.4 M.Similar Executives
| Found 12 records | CHAIRMAN Age | ||
| Douglas Treco | Inozyme PharmaInc | 66 | |
| Philip FSA | Replimune Group | 53 | |
| Terry Rosen | Arcus Biosciences | 64 | |
| Troy Wilson | Kura Oncology | 49 | |
| MPH Coles | Cerevel Therapeutics Holdings | 64 | |
| Mark Iwicki | Merus BV | 50 | |
| Michael Wyzga | X4 Pharmaceuticals | 63 | |
| Harold Selick | Protagonist Therapeutics | 63 | |
| Joseph Gutnick | Cullinan Oncology LLC | 63 | |
| Yves Sabbagh | Inozyme PharmaInc | N/A | |
| Dennis Podlesak | Syndax Pharmaceuticals | 60 | |
| Philip AstleySparke | Replimune Group | 45 | |
Management Performance
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 |
Mersana Therapeutics Leadership Team
Elected by the shareholders, the Mersana Therapeutics' board of directors comprises two types of representatives: Mersana Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mersana. The board's role is to monitor Mersana Therapeutics' management team and ensure that shareholders' interests are well served. Mersana Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mersana Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Damelin, Oncology, Biology | ||
| Ashish Mandelia, Vice President Controller | ||
| Mohan Bala, Senior Officer | ||
| Tushar Misra, Senior Officer | ||
| Eva Jack, Chief Business Officer | ||
| MD Huber, CEO President | ||
| Willard Dere, Independent Director | ||
| Michael Kaufman, Senior Vice President - Chemistry, Manufacturing and Controls | ||
| Andrew Hack, Independent Director | ||
| Wayne Foster, Vice President - Finance | ||
| Dirk Huebner, Chief Medical Officer | ||
| Anna MBA, CEO Pres | ||
| Brian DeSchuytner, Senior Vice President - Finance and Product Strategy | ||
| Chuck Miller, Senior Affairs | ||
| Carla Poulson, Chief Officer | ||
| Martin MD, CEO President | ||
| Jason Fredette, Senior Communications | ||
| David Spellman, CFO | ||
| Lawrence Alleva, Independent Director | ||
| Anna Protopapas, President CEO, Director | ||
| Timothy Lowinger, Chief Scientific Officer | ||
| Donald Bergstrom, Chief Medical Officer | ||
| Kristen Hege, Independent Director | ||
| Alejandra JD, Secretary SVP | ||
| David Mott, Chairman of the Board | ||
| Mikhail Papisov, CoFounder |
Mersana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mersana Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.66 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (1.96) % | ||||
| Current Valuation | 181.38 M | ||||
| Shares Outstanding | 121.3 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 95.29 % | ||||
| Number Of Shares Shorted | 10.58 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 12.49 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Mersana Stock analysis
When running Mersana Therapeutics' price analysis, check to measure Mersana Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mersana Therapeutics is operating at the current time. Most of Mersana Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mersana Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mersana Therapeutics' price. Additionally, you may evaluate how the addition of Mersana Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Mersana Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.317 | Quarterly Revenue Growth (0.27) | Return On Assets (0.38) | Return On Equity (2.66) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.